BRIGHENTI, Matteo
 Distribuzione geografica
Continente #
NA - Nord America 141
EU - Europa 106
AS - Asia 29
Totale 276
Nazione #
US - Stati Uniti d'America 141
IE - Irlanda 54
SE - Svezia 33
CN - Cina 19
DE - Germania 9
SG - Singapore 8
FI - Finlandia 4
IN - India 2
IT - Italia 2
RU - Federazione Russa 2
BE - Belgio 1
UA - Ucraina 1
Totale 276
Città #
Chandler 57
Dublin 54
Ashburn 15
Shanghai 13
New York 12
Bremen 8
Princeton 8
Dearborn 5
Helsinki 4
Boardman 3
Nanjing 2
Pune 2
Singapore 2
Ann Arbor 1
Brussels 1
Des Moines 1
Jinan 1
Nanning 1
Norwalk 1
Shenyang 1
Tianjin 1
Vladikavkaz 1
Totale 194
Nome #
Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRC-AIFA FARM6PMFJM trial 45
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 41
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 41
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer 37
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report 36
Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen 30
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: Results of a phase II trial 29
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 26
Totale 285
Categoria #
all - tutte 1.394
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.394


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 2 0 0 0 1 5 0 0 1 0 0 0
2021/202225 0 0 0 0 0 0 9 1 0 2 0 13
2022/2023180 19 21 15 6 18 19 0 12 66 0 2 2
2023/202465 1 9 0 1 2 28 8 2 2 0 8 4
Totale 285